Drug intelligence / Profile preview

AZD-1705

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Subcutaneous

Overview

AZD-1705 is an investigational drug developed by AstraZeneca for the treatment of dyslipidemia. It is currently in Phase I clinical trials. The drug is administered subcutaneously and acts by targeting angiopoietin-like protein 3 (ANGPTL3), a regulator of lipid metabolism. By modulating ANGPTL3 protein expression, AZD-1705 aims to reduce abnormal blood lipid levels, potentially offering a new therapeutic option for patients with dyslipidemia.

Targets

ANGPTL3 (Angiopoietin-like protein 3)

Beyond the preview

Go deeper on AZD-1705.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD-1705.

Explore the full profile